BIO-TECHNE Stock Price, News & Analysis (NASDAQ:TECH)

BIO-TECHNE trades on the NASDAQ under the ticker symbol "TECH."

BIO-TECHNE declared a quarterly dividend on Tuesday, August 6th. Stockholders of record on Friday, August 16th will be paid a dividend of $0.32 per share on Friday, August 30th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 0.63%. The ex-dividend date is Thursday, August 15th. View BIO-TECHNE's Dividend History.

BIO-TECHNE Corp (NASDAQ:TECH) announced its earnings results on Tuesday, August, 6th. The biotechnology company reported $1.25 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.17 by $0.08. The biotechnology company had revenue of $191.66 million for the quarter, compared to analyst estimates of $196.37 million. BIO-TECHNE had a net margin of 13.45% and a return on equity of 13.20%. The company's revenue was up 6.3% compared to the same quarter last year. During the same period last year, the business earned $1.34 earnings per share. View BIO-TECHNE's Earnings History.

BIO-TECHNE is scheduled to release their next quarterly earnings announcement on Tuesday, October 29th 2019. View Earnings Estimates for BIO-TECHNE.

BIO-TECHNE will be holding an earnings conference call on Tuesday, October 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

6 analysts have issued twelve-month target prices for BIO-TECHNE's stock. Their predictions range from $165.00 to $270.00. On average, they anticipate BIO-TECHNE's stock price to reach $206.80 in the next year. This suggests a possible upside of 1.7% from the stock's current price. View Analyst Price Targets for BIO-TECHNE.

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BIO-TECHNE in the last year. There are currently 2 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BIO-TECHNE.

News headlines about TECH stock have been trending very negative on Thursday, according to InfoTrie Sentiment. InfoTrie rates the sentiment of media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. BIO-TECHNE earned a coverage optimism score of -3.1 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near term. View News Stories for BIO-TECHNE.

BIO-TECHNE saw a increase in short interest in the month of September. As of September 15th, there was short interest totalling 799,800 shares, an increase of 8.1% from the August 15th total of 739,700 shares. Based on an average daily volume of 166,700 shares, the short-interest ratio is presently 4.8 days. Approximately 2.1% of the shares of the stock are sold short. View BIO-TECHNE's Current Options Chain.

Some companies that are related to BIO-TECHNE include Seattle Genetics (SGEN), NOVOZYMES A/S/S (NVZMY), Neurocrine Biosciences (NBIX), Qiagen (QGEN), bluebird bio (BLUE), Moderna (MRNA), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Ablynx (ABLYF), Spark Therapeutics (ONCE), Adaptive Biotechnologies (ADPT), Allogene Therapeutics (ALLO), Iovance Biotherapeutics (IOVA) and Halozyme Therapeutics (HALO).

Based on aggregate information from My MarketBeat watchlists, some companies that other BIO-TECHNE investors own include Paychex (PAYX), Global Medical REIT (GMRE), Celgene (CELG), Gilead Sciences (GILD), AbbVie (ABBV), General Electric (GE), Amgen (AMGN), Crispr Therapeutics (CRSP), GW Pharmaceuticals PLC- (GWPH) and Illumina (ILMN).

BIO-TECHNE's stock is owned by many different of institutional and retail investors. Top institutional shareholders include Riverbridge Partners LLC (1.05%), Summit Creek Advisors LLC (0.22%), Envestnet Asset Management Inc. (0.06%), Palisade Asset Management LLC (0.04%), Pacer Advisors Inc. (0.04%) and Tributary Capital Management LLC (0.03%). Company insiders that own BIO-TECHNE stock include Brenda S Furlow, Charles A Dinarello, Charles R Kummeth, James Hippel, John L Higgins, Norman David Eansor and Robert V Baumgartner. View Institutional Ownership Trends for BIO-TECHNE.

TECH stock was sold by a variety of institutional investors in the last quarter, including Riverbridge Partners LLC, Pacer Advisors Inc., Palisade Asset Management LLC, Meeder Asset Management Inc., NEXT Financial Group Inc, Crossmark Global Holdings Inc. and Argus Investors Counsel Inc.. Company insiders that have sold BIO-TECHNE company stock in the last year include Brenda S Furlow, Charles R Kummeth, James Hippel, John L Higgins and Norman David Eansor. View Insider Buying and Selling for BIO-TECHNE.

TECH stock was bought by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, State of Alaska Department of Revenue, Envestnet Asset Management Inc., Tributary Capital Management LLC, Navellier & Associates Inc, Clarus Wealth Advisors and Diversified Trust Co. Company insiders that have bought BIO-TECHNE stock in the last two years include Charles R Kummeth and Robert V Baumgartner. View Insider Buying and Selling for BIO-TECHNE.

Shares of TECH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of TECH stock can currently be purchased for approximately $203.32.

BIO-TECHNE has a market capitalization of $7.70 billion and generates $714.01 million in revenue each year. The biotechnology company earns $96.07 million in net income (profit) each year or $3.80 on an earnings per share basis. BIO-TECHNE employs 2,250 workers across the globe.View Additional Information About BIO-TECHNE.

The official website for BIO-TECHNE is http://www.techne-corp.com/.

BIO-TECHNE's mailing address is 614 MCKINLEY PLACE NE, MINNEAPOLIS MN, 55413. The biotechnology company can be reached via phone at 612-379-8854 or via email at [email protected]